Barclays Maintains an 'Underweight' on Boston Scientific (BSX); FDA Approval of Promus Element Sooner than Expected; Adjusting Estimates
Go back to Barclays Maintains an 'Underweight' on Boston Scientific (BSX); FDA Approval of Promus Element Sooner than Expected; Adjusting Estimates| Boston Scientific (NYSE: BSX) | Delayed: 50.47 -0.96 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.43 | 52 Week High | $24.79 | |||
| Open | $52.38 | 52 Week Low | $15.67 | |||
| Day High | $52.53 | P/E | N/A | |||
| Day Low | $50.45 | EPS | $-0.09 | |||
| Volume | 11,797,363 | |||||
